Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by recurrent abdominal pain, altered bowel habits, and bloating, in the absence of identifiable structural or inflammatory pathology. It affects approximately one in five adults in the UK and is one of the most common reasons for gastroenterology referral. It is important to understand from the outset that IBS is not the same as inflammatory bowel disease (IBD). Crohn's disease and ulcerative colitis are inflammatory conditions with identifiable mucosal changes; IBS is functional — there is no inflammation to be seen on colonoscopy or biopsy.

IBS vs IBD: An Important Distinction

Patients and clinicians often find that distinguishing IBS from IBD is critical for treatment planning. IBD involves chronic, immune-mediated inflammation of the gastrointestinal tract and is associated with measurable biomarkers including elevated faecal calprotectin, elevated CRP, and visible mucosal damage on endoscopy. IBS, by contrast, involves normal inflammatory markers and normal bowel appearance. This distinction matters for the cannabis prescribing pathway: in IBD, the anti-inflammatory properties of cannabinoids (particularly CBD via CB2 receptor signalling) are part of the rationale. In IBS, the mechanisms are different — primarily involving the modulation of gut motility, visceral pain sensitivity, and the gut-brain axis.

It is also worth noting that a significant number of patients with IBD also have functional IBS-like symptoms even when their IBD is in remission. If you have been diagnosed with both, your specialist will need to understand which symptoms are driving your current presentation.

The Endocannabinoid System in the GI Tract

The endocannabinoid system is extensively expressed throughout the gastrointestinal tract. CB1 receptors are found on enteric neurons throughout the gut wall, where they modulate peristalsis, secretion, and visceral sensation. CB2 receptors are expressed on immune cells in the gut mucosa and play a role in inflammatory signalling. The enteric nervous system — sometimes referred to as the gut brain — is richly innervated with endocannabinoid-responsive neurons, and disruption of endocannabinoid tone has been proposed as one mechanism contributing to IBS pathophysiology.

THC, via CB1 receptor agonism, can reduce colonic motility, decrease visceral pain sensitivity, and reduce intestinal secretion. These effects are potentially relevant for IBS-D (diarrhoea-predominant IBS) where accelerated transit and hypersensitivity are primary features. CBD modulates gut inflammation, has anxiolytic properties relevant to the anxiety-IBS comorbidity, and may influence gut permeability. The combined effects of THC and CBD in whole-plant preparations may offer broader activity across the range of IBS symptom domains.

IBS Subtypes and Therapeutic Considerations

IBS is classified by predominant bowel habit: IBS-C (constipation-predominant), IBS-D (diarrhoea-predominant), IBS-M (mixed), and IBS-U (unclassified). The subtype matters for cannabis prescribing because the effects of cannabinoids on gut motility vary. THC inhibitory effect on gut transit may be beneficial in IBS-D but theoretically unhelpful in IBS-C. CBD effects on motility are less pronounced. In practice, specialists will consider the patient predominant symptom pattern when selecting a formulation. Most clinical experience with cannabis-based medicines in IBS has been in patients with IBS-D and mixed-type IBS where visceral pain and diarrhoea are prominent.

Evidence Base: Honest Assessment

The evidence for cannabis-based medicines specifically in IBS is emerging but not yet definitive. There are no large-scale, double-blind, placebo-controlled randomised controlled trials of cannabis-based medicines in IBS. Observational data and smaller studies suggest improvements in abdominal pain, visceral hypersensitivity, and overall quality of life in some patients. The anxiety-IBS bidirectional relationship is also clinically important. Anxiety is both a cause and consequence of IBS symptoms, and the gut-brain axis means that psychological stress directly influences gut function. CBD anxiolytic effects may contribute to IBS symptom improvement via this pathway, independently of direct GI effects.

First-Line Treatments Before Cannabis

Before a medical cannabis prescription is considered for IBS, patients are expected to have engaged with standard management. NICE Guideline CG61 (Irritable Bowel Syndrome in Adults) recommends dietary modification (including low-FODMAP diet under dietitian supervision), antispasmodic agents (such as mebeverine or hyoscine), loperamide for IBS-D, laxatives for IBS-C, low-dose tricyclic antidepressants for pain modulation, and psychological therapies including gut-directed CBT. Where these have been tried and found inadequate, or where side effects or contraindications limit their use, a specialist assessment for cannabis-based medicines may be appropriate.

Who May Qualify and How to Access Assessment

Patients most likely to be considered for cannabis prescribing for IBS are those with: a confirmed IBS diagnosis (Rome IV criteria), documented subtype; evidence of inadequate response to dietary modification and standard pharmacological treatment; significant functional impairment attributable to IBS symptoms; no unexcluded IBD (appropriate investigations having been completed). A gastroenterology letter confirming diagnosis and treatment history is valuable. A GP referral is not required by most private cannabis clinics. See UK medical cannabis clinics and how to get a prescription for guidance on the assessment process.

Frequently Asked Questions

Is IBS the same as Crohn's disease or colitis?

No. IBS is a functional disorder — there is no inflammation visible on colonoscopy and inflammatory markers are normal. Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) involving chronic, immune-mediated mucosal inflammation with measurable pathological changes. The two conditions have different causes, different diagnostic criteria, and different treatment pathways.

Can I get a medical cannabis prescription specifically for IBS in the UK?

Yes, in principle. There is no approved-indication list for cannabis-based medicines. A GMC-registered specialist can prescribe where there is a clinical need and where conventional treatments have been inadequate. IBS with significant functional impairment that has not responded to dietary modification, antispasmodics, antidepressants, and psychological therapies is a reasonable basis for specialist assessment.

Which IBS subtype is most likely to benefit from medical cannabis?

Clinical experience and the pharmacology of cannabinoids suggest that IBS-D (diarrhoea-predominant) and IBS-M (mixed) may see the most benefit, particularly in terms of pain and transit effects from THC. IBS-C (constipation-predominant) requires more careful formulation selection, as THC inhibitory effect on gut motility could theoretically worsen constipation. Your prescribing specialist will consider your subtype when selecting a formulation.

Will cannabis help with IBS anxiety as well as gut symptoms?

The gut-brain axis means that anxiety and IBS are closely interrelated. CBD has documented anxiolytic properties and may reduce the psychological component of IBS symptom amplification. Many patients report improvements in both gut symptoms and anxiety when using a CBD-containing preparation.

Do I need a gastroenterologist referral to get medical cannabis for IBS?

A GP referral to a private cannabis clinic is not required by most providers. However, a letter or documentation from a gastroenterologist confirming your IBS diagnosis, subtype, and treatment history is very useful and in some cases expected. Having a clear documented history of your diagnosis and treatments — including dietary modifications, medications trialled, and any psychological interventions — will support the assessment process.

How Much Does Medical Cannabis Cost for IBS in the UK?

• Initial consultation: £79 to £200 depending on the clinic.
• Monthly medication: £100 to £400 per month, depending on product type and dose.
• Follow-up appointments: £50 to £100 per session, typically every one to three months.

Compare the full cost structure — including whether follow-up appointments are included in a monthly package — before committing to a clinic. See the full UK cost guide for a detailed breakdown.